A peptide with at least 16 residues and the general formula Sub 1 -X 1 NX 2 X 3 PVYIPX 4 X 5 RPPHP-Sub 2 wherein X 1 is a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 2 is a residue with a polar side chain or a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 3 is a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 4 is a neutral residue with a polar side chain, not glutamine, or a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 5 is proline or a proline derivate; Sub 1 being the free N-Terminal amino group of the amino acid X 1 or a modification of the N-terminal amino group with the general formula NR 1 R 2, whereas R 1 and R 2 are independent from each other selected from hydrogen or the groups consisting of: (i) a straight chain, branched, cyclic or heterocyclic alkyl group, such as methyl, ethyl, npropyl, isopropyl, n-butyl, isobutyl, cyclohexyl; (ii) a straight chain, branched, cyclic or heterocyclic alkanoyl group, such as acetyl ormethanoyl (formyl), propionyl, n-butyryl, isobutyryl, pentanoyl, hexanoyl, or cyclohexanoyl; (iii) a reporter group, such as a fluorescent dye or biotin; (iv) a linker bridging the N- and C-termini of the peptide to obtain a cyclic peptide, e. g. based on guanidine, ethyleneglycol oligomers, 2,4-diaminobutanoic acid, 2,3-diaminipropionic acid, 2,2'-diaminopimelic acid, desmosin, or isodesmosine; Sub 2 being the free C-terminal carboxyl group of the c-terminal amino acid or a modification of the C-terminal carboxyl group, wherein X1 still carries a positive charge after modification with Sub 1. X 1 is a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 2 is a residue with a polar side chain or a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 3 is a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 4 is a neutral residue with a polar side chain, not glutamine, or a moiety having a net positive charge or a positively charged side chain under physiological conditions; X 5 is proline or a proline derivate; Sub 1 being the free N-Terminal amino group of the amino acid X 1 or a modification of the N-terminal amino group with the general formula NR 1 R 2, whereas R 1 and R 2 are independent from each other selected from hydrogen or the groups consisting of: (i) a straight chain, branched, cyclic or heterocyclic alkyl group, such as methyl, ethyl, npropyl, isopropyl, n-butyl, isobutyl, cyclohexyl; (ii) a straight chain, branched, cyclic or heterocyclic alkanoyl group, such as acetyl ormethanoyl (formyl), propionyl, n-butyryl, isobutyryl, pentanoyl, hexanoyl, or cyclohexanoyl; (iii) a reporter group, such as a fluorescent dye or biotin; (iv) a linker bridging the N- and C-termini of the peptide to obtain a cyclic peptide, e. g. based on guanidine, ethyleneglycol oligomers, 2,4-diaminobutanoic acid, 2,3-diaminipropionic acid, 2,2'-diaminopimelic acid, desmosin, or isodesmosine; (i) a straight chain, branched, cyclic or heterocyclic alkyl group, such as methyl, ethyl, npropyl, isopropyl, n-butyl, isobutyl, cyclohexyl; (ii) a straight chain, branched, cyclic or heterocyclic alkanoyl group, such as acetyl ormethanoyl (formyl), propionyl, n-butyryl, isobutyryl, pentanoyl, hexanoyl, or cyclohexanoyl; (iii) a reporter group, such as a fluorescent dye or biotin; (iv) a linker bridging the N- and C-termini of the peptide to obtain a cyclic peptide, e. g. based on guanidine, ethyleneglycol oligomers, 2,4-diaminobutanoic acid, 2,3-diaminipropionic acid, 2,2'-diaminopimelic acid, desmosin, or isodesmosine; Sub 2 being the free C-terminal carboxyl group of the c-terminal amino acid or a modification of the C-terminal carboxyl group, wherein X1 still carries a positive charge after modification with Sub 1.